WO1999055302A1 - Composition destinee au traitement du vieillissement de la peau - Google Patents

Composition destinee au traitement du vieillissement de la peau Download PDF

Info

Publication number
WO1999055302A1
WO1999055302A1 PCT/US1999/008497 US9908497W WO9955302A1 WO 1999055302 A1 WO1999055302 A1 WO 1999055302A1 US 9908497 W US9908497 W US 9908497W WO 9955302 A1 WO9955302 A1 WO 9955302A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
composition
cells
effective amount
adp
Prior art date
Application number
PCT/US1999/008497
Other languages
English (en)
Inventor
Thomas Mammone
Donald F. Collins
Original Assignee
Color Access, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Color Access, Inc. filed Critical Color Access, Inc.
Priority to KR10-1999-7012177A priority Critical patent/KR100426753B1/ko
Priority to EP99919884A priority patent/EP1003473A1/fr
Priority to JP55424999A priority patent/JP2001503447A/ja
Priority to CA002294482A priority patent/CA2294482C/fr
Priority to AU37504/99A priority patent/AU744295B2/en
Publication of WO1999055302A1 publication Critical patent/WO1999055302A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the invention relates to cosmetic and pharmaceutical compositions.
  • the invention relates to cosmetic and pharmaceutical compositions which enhance skin cell energy and rejuvenate aging skin cells.
  • the present invention now provides a means for enhancing the ATP levels of aged fibroblasts.
  • the invention provides a method for increasing ATP levels in aging cells which comprises applying to the skin an effective amount of ADP, AMP, or oxaloacetic acid, or a combination thereof.
  • the method is particularly useful in increasing energy in skin cells, particularly fibroblasts.
  • the invention also provides cosmetic and pharmaceutical compositions for topical application to the skin comprising effective amounts of ADP, AMP, or oxaloacetate, or a combination thereof in a cosmetically or pharmaceutically acceptable carrier.
  • the terms "ADP", "AMP” and "oxaloacetic acid” shall include safe and effective derivatives thereof which retain qualitatively the same activity.
  • the present invention is based on an observation that the extrinsic provision of ADP, AMP or oxaloacetic acid (oxaloacetate) to skin cells results in an increase of cell energy present in the cells so treated.
  • ADP, AMP or oxaloacetic acid is provided to normal fibroblasts in culture, ATP levels can be increased substantially.
  • use of ADP and/or AMP and/or oxaloacetic acid as active agents in the treatment and prevention of skin aging is indicated.
  • compositions of the invention comprise effective amounts of ADP, AMP or a combination thereof, in combination with a cosmetically or pharmaceutically acceptable carrier.
  • effective amount is meant that amount of the active agent which can increase the amount of ATP in a treated cell at least about 10%, preferably at least about 20%, more preferably at least about 30%, and most preferably at least about 40%, relative to untreated cells.
  • concentration of the active agent will be from about 0.001-10%, preferably about 0.01-5%, by weight of the total composition; the concentration may be varied depending upon the intended frequency of use of the composition, lower concentrations being employed with more frequent applications.
  • the active components can be formulated with a variety of cosmetically and/or pharmaceutically acceptable carriers.
  • pharmaceutically or cosmetically acceptable carrier refers to a vehicle, for either pharmaceutical or cosmetic use, which vehicle delivers the active components to the intended target and which will not cause harm to humans or other recipient organisms.
  • pharmaceutical or cosmetic will be understood to encompass both human and animal pharmaceuticals or cosmetics.
  • Useful carriers include, for example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1, 3-diol, isopropyl myristate, isopropyl palmitate, or mineral oil.
  • the carrier may be in any form appropriate to the mode of delivery, for example, solutions, colloidal dispersions, emulsions (oil-in-water or water-in- oil) , suspensions, creams, lotions, gels, foams, mousses, sprays and the like.
  • the active agents of the invention can be used alone to increase the energy level of skin cells generally, so as to delay or reverse the onset of the cellular symptoms of aging.
  • aging as used in the present specification and claims, is meant both photoaging, i.e., the premature aging which occurs as the result of excessive exposure to UV rays, and chronological aging, i.e., the naturally occurring, normal aging of the skin which occurs over time, even without prolonged sun exposure.
  • the compositions of the invention are particularly suited for enhancing the energy levels of fibroblasts and keratinocytes in both normal and aging skin. Increase in energy levels of fibroblasts can be expected to delay or reverse the decrease in collagen and elastin production that characterizes aged fibroblasts.
  • the increase in energy levels of keratinocytes can be expected to result in a delay in the thinning of the epidermis observed in aging skin.
  • the use of the active agents of the invention is not limited to skin cells, however, but may also be expected to aid in energy increase in, for example, aging muscle or other connective tissue cells.
  • Treatment of aging skin, or prevention of aging in normal, non-aged skin is preferably achieved by regular application of the composition over a period of time.
  • a preferred method of obtaining the benefits of the composition is via chronic topical application of a safe and effective amount of a composition containing the mixture, to prevent or delay development of skin damage which may result from photo- or chronoaging, or to prevent worsening of or to reverse already established damage.
  • topical application of the composition in an amount of from about 0.1 ⁇ g/cm 2 to 2 mg/cm 2 of exposed skin, be performed from about once per week to about 4 or 5 times daily, preferably from about 3 times a week to about 3 times daily, most preferably about once or twice per day.
  • chromenic application it is meant herein that the period of topical application may be over the lifetime of the user, preferably for a period of at least about one month, more preferably from about three months to about twenty years, more preferably from about six months to about ten years, more preferably still from about one year to about five years, thereby resulting in the treatment or prevention of the external signs of photoaging and chronological aging.
  • the compositions of the invention may also be used on a less frequent basis, for example, once or twice a month, as a sort of "spa treatment" with a higher level of active component provided on these occasions.
  • the external signs of aging that the composition may alleviate include, but are not limited to, fine and deep lines and wrinkles, skin atrophy, reduction in skin thickness, changes in skin pigmentation, and reduction in hair growth.
  • the actives of the invention can also be combined with other anti-aging or skin-enhancing agents.
  • the actives of the invention can be combined, for example, with one or more of the following products: alpha- or beta- hydroxy acids, such as lactic acid, glycolic acid, citric acid, alpha-hydroxyoctanoic acid, alpha-hydroxydecanoic acid, alpha-hydroxylauric acid, tartaric acid, glucouronic acid, galactouronic acid, alpha-hydroxybutyric acid, alpha- hydroxyisobutyric acid, malic acid, mandelic acid, pyruvic acid, and tartronic acid, and salicylic acid; retinoids, such as retinol, retinyl acetate, retinyl palmitate, retinyl butyrate, retinyl oleate, retinyl linoleate, and retinoic acid; and DHEA and derivatives thereof.
  • alpha- or beta- hydroxy acids
  • the formulation in addition to the carrier and active agents, also can comprise other components which may be chosen depending on the carrier and/or the intended use of the formulation. Additional components include, but are not limited to, water soluble colorants (such as FD&C Blue #1) ; oil soluble colorants (such as D&C Green #6) ; water soluble sunscreens (such as Eusolex 232) ; oil soluble sunscreens (such as octyl methoxycinnamate) ; particulate sunscreens (such as zinc oxide) ; antioxidants (such as BHT) ; chelating agents (such as disodium EDTA) ; emulsion stabilizers (such as carbomer) ; preservatives (such as methyl paraben) ; fragrances (such as pinene) ; flavoring agents (such as sorbitol) ; humectants (such as glycerine) ; waterproofing agents (such as PVP/Eicosene Copolymer) ; water soluble film
  • compositions can be therapeutic products, ADP and/or AMP and/or oxaloacetic acid being the sole actives, or in combination with other actives.
  • the compositions can also be a makeup products, for example, a lipstick, foundation, concealer, bronzer, blush, eyeshadow and the like.
  • This example illustrates the increase in cell energy levels produced by treatment of cells with ADP or AMP.
  • Normal human dermal fibroblasts are grown to confluence in flasks, and then divided into three different treatment sets. Testing is done at the point at which the cells have undergone 32 population doublings. The treatments are with ADP (Sigma), AMP(Yamasa Shoyu Co., Inc.), and creatine monophosphate (Sigma) , each at five different concentrations ranging from 0.01-1.0 mM. The growth medium serves as a control.
  • the cells are treated for a period of 2 hours, and then trypsinized, washed and resuspended to 6X10 6 cells/ml.
  • the cells are treated with a releasing agent, sodium lauryl sulfate, which causes the ATP contained within the cells to be released.
  • the releasate is then added to a solution containing luciferin and luciferase.
  • Luciferase utilizes the energy provided by free ATP to convert luciferin to oxyluciferin.
  • the light released by this reaction is read on a spectrophotometer; the amount produced is proportional to the amount of ATP available.
  • the ATP levels are calculated from an ATP standard curve, and then normalized on a per cell basis. The results are shown in Table 1. TABLE 1
  • This example illustrates the increase in cell energy levels produced by treatment of cells with oxaloacetic acid.
  • Normal human dermal fibroblasts are grown to subconfluence in flasks, treated with oxaloacetic acid for two hours with three samples, having concentrations of 0.05 mM, 0.50mM and 1.0 mM. The cells are then trypsinized, washed and resuspended to 6X10 6 cells/ml. The treated cells have undergone four passages. The cells are further treated and analyzed as described in the previous example, with the amount of ATP calculated at the various dosages. The results are shown in Table 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition s'utilisant en application locale sur la peau et comprenant une quantité suffisante d'adénosine-diphosphate, d'adénosine-monophosphate, d'acide oxaloacétique ou de l'une quelconque de leurs combinaisons, associée à un excipient de type cosmétique ou pharmaceutique. Les compositions de l'invention sont susceptibles de convenir au relèvement du niveau d'énergie des cellules, notamment des cellules de la peau, ainsi qu'au traitement et à la prévention des symptômes du vieillissement de la peau.
PCT/US1999/008497 1998-04-27 1999-04-22 Composition destinee au traitement du vieillissement de la peau WO1999055302A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR10-1999-7012177A KR100426753B1 (ko) 1998-04-27 1999-04-22 피부 노화 치료 조성물 및 방법
EP99919884A EP1003473A1 (fr) 1998-04-27 1999-04-22 Composition destinee au traitement du vieillissement de la peau
JP55424999A JP2001503447A (ja) 1998-04-27 1999-04-22 老化皮膚の処置用組成物および方法
CA002294482A CA2294482C (fr) 1998-04-27 1999-04-22 Traitement du vieillissement de la peau
AU37504/99A AU744295B2 (en) 1998-04-27 1999-04-22 Composition and method for treatment of aging skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6705998A 1998-04-27 1998-04-27
US09/067,059 1998-04-27

Publications (1)

Publication Number Publication Date
WO1999055302A1 true WO1999055302A1 (fr) 1999-11-04

Family

ID=22073462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/008497 WO1999055302A1 (fr) 1998-04-27 1999-04-22 Composition destinee au traitement du vieillissement de la peau

Country Status (6)

Country Link
EP (1) EP1003473A1 (fr)
JP (1) JP2001503447A (fr)
KR (1) KR100426753B1 (fr)
AU (1) AU744295B2 (fr)
CA (1) CA2294482C (fr)
WO (1) WO1999055302A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186754B2 (en) 1999-06-25 2007-03-06 Avicena Group, Inc. Use of creatine or creatine compounds for skin preservation
EP1824470A2 (fr) * 2004-12-17 2007-08-29 Alan Brian Cash Procede d'extension de la duree de vie et de retardement de l'apparition de maladies associees au vieillissement
WO2010147238A1 (fr) * 2009-06-19 2010-12-23 Otsuka Pharmaceutical Co., Ltd. Agent destine a prevenir ou a traiter une anomalie de la fonction de permeation de l'eau dans la peau
US7994153B2 (en) 2002-05-20 2011-08-09 Otsuka Pharmaceutical Co., Ltd. Chloasma amelioration composition and dullness amelioration composition
US8492353B2 (en) 2002-08-06 2013-07-23 Otsuka Pharmaceutical Co., Ltd. Antiaging composition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5093998B2 (ja) * 2004-09-22 2012-12-12 大塚製薬株式会社 色素沈着予防又は改善剤
KR101283303B1 (ko) * 2007-01-31 2013-07-12 (주)아모레퍼시픽 조성물 내 ｐＨ 조절을 통해 안정화된 α­케토 산(α­ｋｅｔｏ ａｃｉｄ)을 함유하는 피부 외용제 조성물 및 그 α­케토 산 안정화 방법
JP2009298752A (ja) * 2008-06-17 2009-12-24 Shiseido Co Ltd 皮膚外用剤組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03236320A (ja) * 1990-02-09 1991-10-22 Kobayashi Kose Co Ltd 皮膚外用剤
JPH0665041A (ja) * 1992-08-17 1994-03-08 Kose Corp 皮膚外用剤
JPH06128140A (ja) * 1992-10-16 1994-05-10 Kose Corp 皮膚外用剤
JPH0899860A (ja) * 1994-09-30 1996-04-16 Kose Corp 皮膚外用剤
JPH09157153A (ja) * 1995-12-11 1997-06-17 Noevir Co Ltd 皮膚外用剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03236320A (ja) * 1990-02-09 1991-10-22 Kobayashi Kose Co Ltd 皮膚外用剤
JPH0665041A (ja) * 1992-08-17 1994-03-08 Kose Corp 皮膚外用剤
JPH06128140A (ja) * 1992-10-16 1994-05-10 Kose Corp 皮膚外用剤
JPH0899860A (ja) * 1994-09-30 1996-04-16 Kose Corp 皮膚外用剤
JPH09157153A (ja) * 1995-12-11 1997-06-17 Noevir Co Ltd 皮膚外用剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9148, Derwent World Patents Index; Class B03, AN 91-350854, XP002900582 *
DATABASE WPI Section Ch Week 9415, Derwent World Patents Index; Class B04, AN 94-121159, XP002900579 *
DATABASE WPI Section Ch Week 9423, Derwent World Patents Index; Class A96, AN 94-188881, XP002900580 *
DATABASE WPI Section Ch Week 9625, Derwent World Patents Index; Class B02, AN 96-246892, XP002900578 *
DATABASE WPI Section Ch Week 9734, Derwent World Patents Index; Class B04, AN 97-369368, XP002900581 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186754B2 (en) 1999-06-25 2007-03-06 Avicena Group, Inc. Use of creatine or creatine compounds for skin preservation
US7994153B2 (en) 2002-05-20 2011-08-09 Otsuka Pharmaceutical Co., Ltd. Chloasma amelioration composition and dullness amelioration composition
US8492353B2 (en) 2002-08-06 2013-07-23 Otsuka Pharmaceutical Co., Ltd. Antiaging composition
EP1824470A2 (fr) * 2004-12-17 2007-08-29 Alan Brian Cash Procede d'extension de la duree de vie et de retardement de l'apparition de maladies associees au vieillissement
EP1824470A4 (fr) * 2004-12-17 2009-07-01 Alan Brian Cash Procede d'extension de la duree de vie et de retardement de l'apparition de maladies associees au vieillissement
AU2005316295B2 (en) * 2004-12-17 2012-03-22 Alan B. Cash Method for extending lifespan and delaying the onset of age-related disease
US10016385B2 (en) 2004-12-17 2018-07-10 Alan B. Cash Method for extending lifespan delaying the onset of age-related disease
US11173139B2 (en) 2004-12-17 2021-11-16 Alan B. Cash Method for extending lifespan delaying the onset of age-related disease
WO2010147238A1 (fr) * 2009-06-19 2010-12-23 Otsuka Pharmaceutical Co., Ltd. Agent destine a prevenir ou a traiter une anomalie de la fonction de permeation de l'eau dans la peau
CN102458351A (zh) * 2009-06-19 2012-05-16 大塚制药株式会社 皮肤水分透过功能异常的预防或治疗剂

Also Published As

Publication number Publication date
JP2001503447A (ja) 2001-03-13
AU3750499A (en) 1999-11-16
KR100426753B1 (ko) 2004-04-13
EP1003473A1 (fr) 2000-05-31
CA2294482C (fr) 2007-01-16
AU744295B2 (en) 2002-02-21
KR20010014120A (ko) 2001-02-26
CA2294482A1 (fr) 1999-11-04

Similar Documents

Publication Publication Date Title
US6337320B1 (en) Reparatives for ultraviolet radiation skin damage
US9974984B2 (en) Combination of monosaccharides with antioxidants and use thereof
US20060204458A1 (en) Anti-aging methods and composition
US20020049253A1 (en) Use of creatine or creatine compounds for skin preservation
JPH1087476A (ja) ヒドロキシ酸またはレチノイドを含有する組成物中の刺激防止剤としてのルリヂサ種子油
US20020044913A1 (en) Cosmetics to support skin metabolism
KR100590141B1 (ko) 화장제 조성물
WO2002015860A1 (fr) Antioxydant topique a base de vitamine c et procede de combinaison avec agent topique par l'utilisateur
KR19990087346A (ko) 새로운 국소 조성물
JP2002504504A (ja) 化粧品組成物における刺激防止剤
EP1261315A2 (fr) Extrait d'echinacea utilise comme stimulant anti-irritant et anti-age dans des compositions cosmetiques
US20120065261A1 (en) Creatine compositions for skin treatment
JP2001002559A (ja) ヒドロキシ酸またはレチノイドを含有する組成物中の抗炎症剤として作用するターメリック
BRPI0905400A2 (pt) uso cosmético de uma composição, composição e dispositivo
CA2294482C (fr) Traitement du vieillissement de la peau
WO2002011717A9 (fr) Cosmetiques destines a aider le metabolisme cutane
US6630442B1 (en) Reparatives for chemosurgery and laser (thermal) therapy
JPH11505818A (ja) フィチン酸含有の化粧品又は皮膚科学的調製物
CN115177565A (zh) 一种美白亮肤组合物及其在化妆品中的应用
CA2590119A1 (fr) Procedes anti-vieillissement et composition associee
JP2002370962A (ja) 美白用化粧料および皮膚老化防止・改善用化粧料
CN100536820C (zh) 含至少一马来酸酐共聚物稳定的至少一氧化敏感亲水活性成分组合物的化妆和/或皮肤应用
Riccardi Reversal of photoaging of the skin by topical d-alpha tocopherol, ascorbic acid, and L-selenomethionine: A comparative analysis performed by light and transmission electron microscopy
BRPI0905229B1 (pt) Cosmetic use of a composition, cosmetic composition, device, and, joint

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2294482

Country of ref document: CA

Ref country code: CA

Ref document number: 2294482

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 37504/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1019997012177

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1999 554249

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999919884

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1999919884

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997012177

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 37504/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1019997012177

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1999919884

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999919884

Country of ref document: EP